Literature DB >> 11597398

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Y Yarden1.   

Abstract

Growth factors and their transmembrane receptor tyrosine kinases play important roles in cell proliferation, survival, migration and differentiation. One group of growth factors, comprising epidermal growth factor (EGF)-like proteins and neuregulins, stimulates cells to divide by activating members of the EGF receptor (EGFR) family, which consists of the EGFR itself and the receptors known as HER2-4. This highly conserved signalling module plays a fundamental role in the morphogenesis of a diverse spectrum of organisms, ranging from humans to nematodes, and has also been implicated in the development and growth of many types of human tumour cells. In humans, more than 30 ligands and the EGFR family of four receptors lie at the head of a complex, multi-layered signal-transduction network. Different activated receptor-ligand complexes vary in both the strength and type of cellular responses that they induce. Analysis of the multiple processes that modulate EGFR signal transduction, such as receptor heterodimerisation and endocytosis, has revealed new therapeutic opportunities and elucidated mechanisms contributing to the efficacy of existing anticancer treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597398     DOI: 10.1016/s0959-8049(01)00230-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  465 in total

1.  Polymorphism of the epidermal growth factor receptor extracellular ligand binding domain: the dimer interface depends on domain stabilization.

Authors:  Zhiyong Zhang; Willy Wriggers
Journal:  Biochemistry       Date:  2011-02-18       Impact factor: 3.162

2.  Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA.

Authors:  B Leticia Rodriguez; Xinran Li; Kaoru Kiguchi; John DiGiovanni; Evan C Unger; Zhengrong Cui
Journal:  Nanomedicine (Lond)       Date:  2012-02-02       Impact factor: 5.307

Review 3.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

4.  Sequential and gamma-secretase-dependent processing of the betacellulin precursor generates a palmitoylated intracellular-domain fragment that inhibits cell growth.

Authors:  Alexander Stoeck; Li Shang; Peter J Dempsey
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

Review 5.  The use of markers for correlative light electron microscopy.

Authors:  Edward Brown; Paul Verkade
Journal:  Protoplasma       Date:  2010-06-05       Impact factor: 3.356

6.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 7.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

8.  Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Authors:  Seok Jin Kim; Zahid N Rabbani; Fan Dong; Robin T Vollmer; Ernst-Gilbert Schreiber; Mark W Dewhirst; Zeljko Vujaskovic; Michael J Kelley
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

9.  Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family.

Authors:  Francisco Llavero; Miriam Luque Montoro; Alazne Arrazola Sastre; David Fernández-Moreno; Hadriano M Lacerda; Luis A Parada; Alejandro Lucia; José L Zugaza
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

Review 10.  HER2 directed therapy for gastric/esophageal cancers.

Authors:  Elizabeth Won; Yelena J Janjigian; David H Ilson
Journal:  Curr Treat Options Oncol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.